ROCO
8432
Market cap67mUSD
Nov 13, Last price
55.20TWD
Name
TSH Biopharm Corporation Ltd
Chart & Performance
P/E
18.74
P/S
1.90
EPS
2.95
Div Yield, %
2.32%
Shrs. gr., 5y
—
Rev. gr., 5y
-0.23%
Revenues
1.12b
+37.59%
Net income
113m
+82.44%
CFO
184m
+442.54%
Dividend
Jun 17, 20241.28 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan and Asia. It offers products for cardiovascular, central nervous, gastrointestinal, and others. The company was founded in 1999 and is headquartered in Taipei city, Taiwan. TSH Biopharm Corporation Limited is a subsidiary of TTY Biopharm Company Limited.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | |||||
Unusual Expense (Income) | |||||
NOPBT | |||||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | |||||
Net income | |||||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | |||||
| Cash flow | |||||
Cash from operating activities | |||||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | |||||
FCF | |||||
| Balance | |||||
Cash | |||||
Long term investments | |||||
Excess cash | |||||
Stockholders' equity | |||||
Invested Capital | |||||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | |||||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | |||||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||